Insmed Inc (INSM)

[jellybean]

You can't get FDA approval without showing that you have a method for producing the drug.

It is always cheaper and (if you are good) more reliable to have control of your facility than use a contract manufacturer. Ask Tercica about this point.

The $4 million they spent on the facility was in the investor interest as it was building the business.

If shareholders can't see this, the company needs new share holders. Every other biotech on the market responds positively to the news that they have taken control of their mfting. Given the quality and cost of this facility, Insmed pps should have risen.

The financial strain on the company was not caused by the Boulder purchase. It was caused by the emergence of Tercica for the reasons stated earlier.